Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S190000, C546S200000, C548S427000, C548S305100, C514S387000, C514S411000
Reexamination Certificate
active
06852725
ABSTRACT:
The present invention is directed to imidazolyl derivatives of the formula:where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors. The derivatives are useful for treating a variety of diseases including acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas.
REFERENCES:
patent: 5128355 (1992-07-01), Carini et al.
patent: HU 218 460 (1987-09-01), None
patent: WO 9404494 (1994-03-01), None
patent: WO 9724119 (1997-07-01), None
patent: WO 9730053 (1997-08-01), None
patent: WO 9743278 (1997-11-01), None
patent: WO 9745425 (1997-12-01), None
patent: WO 9827108 (1998-06-01), None
Miller, William H. et al.; Chem. Abstract 127:161822; 1997.
Papageorgiou, Christos et al.; “A Non-peptide ligand for the Somatostatin Receptor having a Benzodiazepinone Structure”; Bioorganic & Medicinal Chemistry Letters; vol. 6, No. 3; pp. 267-272; XP004135075; 1996.
Stocker, Fred B. et al.; Chem. Abstract 72:121434; 1970.
Towliati, Hossein; Chem. Abstract 74:53642; 1971.
von Geldern, Thomas W. et al.; Chem Abstract 124:193276, 1996.
von Geldern, Thomas W. et al.; Chem. Abstract 124:127005, 1996.
von Geldern, Thomas W. et al.; Chem. Abstract 124:164291, 1996.
Albert, Rainer, et al.; “Direct Synthesis of [DOTA-Dphe1]-Octreotide (SMT487) : . . . ”; Bioorganic & Medicinal Chemistry Letters, vol. 8; pp. 1207-1210; XP002124712; 1998.
Bornowski, Heinz et al.; Chem. Abstract 78:13689, 1973.
Gordon, Thomas D. et al.; Chem. Abstract 127:248417; 1997.
Gramberg, Dieter et al; “Synthesis of a Type Vibeta-Turn Peptide . . . ”; Helvetica Chimica Acta; vol. 78, pp. 1588-1606; XP000612160; 1995.
Hirschmann, Ralph et al.; “De Novo Design and Synthesis of Somatostatin . . . ”; Journal of the American Chemical Society; vol. 115, No. 26; pp. 12550-12568; XP002124710; 1993.
Hirschmann, Ralph et al.; “Nonpeptidal Peptidomimetics with a beta-D-glucose Scaffolding”; Journal of the American Chemical Society; vol. 114, No. 23; XP002124711; 1992.
Galcera Marie-Odile
Gordon Thomas D.
Moinet Christophe Philippe
Morgan Barry A.
Poitout Lydie Francine
Feeney Alan F.
Fish & Richardson
Liu Hong
Morrill Brian R.
Raymond Richard L.
LandOfFree
Imidazolyl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolyl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3484409